Introduction
Melanoma carries a dismal prognosis with an increasing incidence reaching 19 cases per 100 000 in Northern Europe and thus constitutes a burden to public health. 1 Cardiac metastasis has been documented in 47.2% of patients with melanoma post-mortem but in the majority of cases it was clinically silent. [2] [3] [4] When cardiac involvement is diagnosed ante-mortem, symptoms are often related to tumour location and varies from functional dyspnoea, chest pain to dizziness, or syncope. 5 Since the introduction of immunotherapy in melanoma management, survival has improved significantly for metastatic disease however when cardiac involvement is present data are lacking in regard to prognosis and response to treatment. 6 
Timeline Case presentation
A 65-year-old Caucasian male was referred from his general practitioner after complaining of fatigue and shortness of breath at moderate exertion for 3-5 weeks. He had no prior medical history and did not use any prescribed medication. A computed tomography (CT) scan of the chest and abdomen revealed multiple enlarged lymph nodes in the mediastinum and retro peritoneum. A large infiltrating tumour was found in the left ventricle along with a small pericardial effusion ( Figure 1A ) and sub-segmental pulmonary atelectasis. At physical examination, heart and lung auscultations were unremarkable and no signs of ascites or peripheral oedema were present. No cutaneous lesions were found though multiple hard subcutaneous masses were felt on palpation of the chest and abdomen. Saturation was 96% while breathing ambient air. Blood pressure was 123/85 mmHg and heart rate 100 b.p.m. The
Time Event Findings
August 2018 Fatigue and dyspnoea.
September 3 Clinical evaluation by general practitioner. September 27
Computed tomography (CT) scan of chest and abdomen. Tumour infiltration in left ventricle and multiple enlarged lymph nodes in the mediastinum and retro peritoneum.
October 2 Hospital consultation and echocardiography ( Figure 1C) . Tumour in the right ventricle and ventricular septum. October 8
Fluorodeoxyglucose positron emission tomography scan ( Figure 1D ).
Multiple fluorodeoxyglucose positive masses in the heart, right lung, and lymph nodes in the groin.
October 9
Biopsy from lymph nodes.
October 13
Pathology shows malignant melanoma. Cardiac evaluation with echocardiography ( Figure 2D-F) . Regression in metastatic size.
December 20 Diarrhoea.
January 7, 2019
Persistent diarrhoea, commences infliximab. January 29
Routine cerebral MRI and CT scan of the chest and abdomen after commencing immunotherapy.
Echocardiography ( Figure 3B and C). Figure 1D ), right lung, and lymph nodes in the thorax and groin. Consistent with the FDG-PET scan multiple cardiac metastases were found on contrast echocardiography ( Figure 1E ) and extensive myocardial infiltration was present on Figure 1F ). No involvement of the cardiac valves was found on echocardiography, cardiac MRI, or FDG-PET. Biopsies taken from FDG positive lymph nodes showed malignant melanoma and subsequent analysis did not reveal BRAF mutation or PD-L1 expression. Shortly after, the patient developed blurred vision and a cerebral MRI revealed metastasis in the left occipital and temporal lobe. To manage symptoms, the patient commenced treatment with prednisolone 50 mg once daily and was subsequently reduced to 12.5 mg daily during the following weeks. Due to the patient's metastatic disease with cerebral involvement, he was referred for combination therapy with ipilimumab 78 mg (anti-CTLA 4 antibody) and nivolumab 235 mg (anti-PD-1 antibody) every third week while on steroid treatment. 8 Cardiac evaluation before ipilimumab and nivolumab treatment showed progression of metastasis in the right ventricle (Figure 2A and B) . Strain analysis revealed reduced global longitudinal strain (GLS) to -15.4% on average and apical sparing consistent with infiltrative disease ( Figure 2C) . 9 Laboratory studies showed elevated N-terminal pro-B-type brain natriuretic peptide (NT-pro-BNP) 1391 ng/L (<300 ng/L) and troponin T, 21 ng/L (<14 ng/L). At the time of second treatment, NT-pro-BNP and troponin T increased to 3774 ng/L and 62 ng/L, respectively, suggestive of myocardial injury secondary to immunotherapy. After completing the third treatment, the patient felt a complete relief of his initial symptoms of dyspnoea and fatigue. Clinical evaluation showed reduction in subcutaneous metastasis and the ECG revealed sinus rhythm with normalization of T waves in the inferior leads. Subsequent echocardiography confirmed reduction in the size of cardiac metastasis ( Figure 2D and E) however GLS score did not improve (-12.9%) on average ( Figure 2F ).
Laboratory studies showed reduced NT-pro-BNP 1074 ng/L and TnT 20 ng/L. Following cardiac evaluation, the patient developed severe colitis for which immunotherapy was discontinued and his gastrointestinal symptoms managed by one treatment of TNF-alpha antibody (infliximab 5 mg/kg) and methylprednisolone 80 mg daily for 1 week. The patient subsequently resumed oral steroid treatment initially with prednisolone 75 mg once daily and was gradually reduced during the following weeks to 25 mg daily. A routine MRI scan performed 3 months after treatment initiation revealed progression of cerebral metastasis and CT scan of the thorax and abdomen showed increase in extra-cardiac metastasis, a small peripheral pulmonary embolus, and no pleural effusions. Clinical evaluation revealed unremarkable ECG ( Figure 3A) , persistent reduction in cardiac metastasis on echocardiography ( Figure 3B ) and a notable improvement in GLS score to -14.9% on average with normalization of contraction pattern and Troponin I < 10 ng/L. No signs of increased pulmonary pressure was observed. Pulmonary embolism was treated with weight-adjusted low-molecular heparin daily. Due to deteriorating cognitive function and progression of extra-cardiac metastasis prednisolone dose was increased to 75 mg daily and the patient was referred to palliative care.
Discussion
We present a case of symptomatic cardiac melanoma, treated with immune checkpoint inhibitors resulting in regression of cardiopulmonary symptoms and reduction in cardiac metastatic size, which persisted 6 weeks after discontinuation of therapy. To our Metastasis of melanoma to the heart in an era of immunotherapy
knowledge, this is the first report of cardiac melanoma treated with both ipilimumab and nivolumab. A decade ago metastatic melanoma had a 5-year survival rate of 5-10% on standard chemotherapies but with the introduction of immunotherapies in 2011 survival rates have been increasing. 10, 11 Nivolumab has significantly prolonged overall survival compared with conventional chemotherapy (dacarbazine) 12 and in CheckMate O67 treatment with ipilimumab and nivolumab prolonged survival compared with ipilimumab after 4 years of follow-up. 13 When cardiac melanoma is present, the most common location is in relation to the right-sided heart chambers.
14 Though melanoma in the heart has been observed in up to 47.2% of patients post-mortem, finding patients presenting with symptoms primarily relating to the cardiovascular system is rare. 2, 3 Patients without cardiac symptoms should therefore be offered a screening of cardiac involvement by ECG, troponins, and NT-pro-BNP and in cases of abnormalities a two-and three-dimensional echocardiography should be performed to identify conditions such as; outflow tract obstruction, pericardial effusion, or signs of pulmonary embolism. In symptomatic cases with significant obstructive tumour masses cardiac surgery might be an option, but even with early surgical intervention prognosis remain poor mainly due to diffuse myocardial infiltration and metastasis in other organ systems. 4 Though the patient had extra-cardiac metastasis that progressed during immunotherapy, this case demonstrates that treatment with ipilimumab and nivolumab vary rarely affects cardiac function and provides clinical benefits in patients with cardiac melanoma.
With the increased use of immune checkpoint inhibitors, toxicity is increasingly recognized as a clinical problem. For patients treated with ipilimumab and nivolumab, the most common symptoms are gastrointestinal. Particular diarrhoea which occurs in up to 30% of patients in clinical trials treated with ipilimumab. 15 The patient discussed did develop immune checkpoint inhibitorinduced colitis and his symptoms were managed by administration of prednisolone and TNF-alpha antibody (infliximab). However, due to the severity of the colitis, the patient was not able to continue immunotherapy. A rare but serious toxic effect is immunemediated myocarditis, which has been reported in 0.27% of patients treated with ipilimumab and nivolumab. 16 This diagnosis should be considered if patients present with clinical deterioration in the weeks following treatment initiation. Brain metastases are common in patients with melanoma and are found in more than 75% of cases at the time of death. 17 Historically prognosis has been poor with a median overall survival of 2-5 months and only 5% surviving in the long-term (>5 years). Due to its poor prognosis randomized phase III trials are warranted but data from a randomized phase II study suggest that this population might benefit from combination therapy as well. 18, 19 In the current case, the patient initially reported regression of cerebral symptoms but had increased cognitive problems and progression of cerebral metastasis on magnetic resonance while on combination therapy.
Conclusion
Despite cerebral progression of melanoma, this case demonstrates clinical benefits of treating cardiac melanoma with ipilimumab and nivolumab causing regression of cardiopulmonary symptoms and metastatic size.
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